Research programme: diabetes therapy - Bexel

Drug Profile

Research programme: diabetes therapy - Bexel

Alternative Names: BLX-1117

Latest Information Update: 05 Sep 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BEXEL Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 08 Nov 2005 Preclinical trials in Type-2 diabetes mellitus in USA (unspecified route)
  • 08 Nov 2005 Data presented at the 41st Annual Meeting of the European Association for the Study of Diabetes (EASD-2005) have been added to the adverse events and Diabetes pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top